Bendamustine (Levact®) Plus Rituximab More Effective Than CHOP-R In Treating Patients With Indolent Non-Hodgkin Lymphoma And Mantle Cell Lymphoma

Treatment with bendamustine plus rituximab (B-R) doubles progression free survival (PFS) compared with current standard of care CHOP-R (69.5 versus 31.2 months; p Results from the StiL NHL-1 study published in The Lancet this week show that a first-line treatment regimen of bendamustine plus rituximab (B-R) doubles progression-free survival (PFS) compared with the most often used treatment CHOP plus rituximab (CHOP-R), in newly diagnosed patients with indolent non-Hodgkin lymphoma (iNHL) and mantle cell lymphoma (MCL).1 Median PFS for patients treated with B-R was 69...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news